Skip to main content
. 2020 Jan 17;13(1):16. doi: 10.3390/ph13010016

Table 6.

Yields and preliminary cell viability data for compounds 19a–f (Series IV) in MUTU-1 and DG-75 Burkitt lymphoma cell lines a.

graphic file with name pharmaceuticals-13-00016-i011.jpg MUTU-1 Cell Viability % DG-75 Cell Viability %
Compound Substitution Yield (%) 10 μM 1 μM 10 μM 1 μM
19a R1=CN, R2=R3=H 30 0 9.0 0 20.6
19b R1=(C=O)OCH2CH3, R2=R3=H 18 0.69 48.9 13.4 9.8
19c R1=(C=O)OCH3, R2=R3=H 15 8.4 15.6 1.4 92.2
19d R1=O(C=O)CH3, R2=CN, R3=H 35 0.69 48.9 1.0 99.4
19e R1=R3=(C=O)OCH3, R2=H 32 10.7 84.7 10.3 101.8
19f R1=R3=(C=O)OCH2CH3, R2=H 15 13.8 13.6 13.8 13.9
Maprotiline 8 - - 73.0 93.1 65.1 102.0
Taxol - - 9.8 30.4 9.9 48.8

a Cell proliferation of MUTU-1 and DG-75 cells was determined with an alamarBlue assay (seeding density 1–5 × 104 cells/mL per well for 96-well plates). Compound concentrations of either 1 μM or 10 μM for 24 h (MUTU-1) or 48 h (DG-75) were used to treat the cells (in triplicate) with control wells containing vehicle ethanol (1% v/v). The mean value for three experiments is shown.